Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06046482 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT06046482: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT06046482 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06046482, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
To learn if magrolimab, along with a combination of commercially-available drugs (cetuximab, pembrolizumab, and docetaxel) can help to control HNSCC in combination with other drugs. The safety of magrolimab will also be studied.
Interventions
- DRUG Pembrolizumab
- DRUG Docetaxel
- DRUG cetuximab
- DRUG Magrolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-11-28 |
| Est. Completion | 2024-08-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06046482
The ClinicalTrials.gov registry entry for NCT06046482 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT06046482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06046482 about?
NCT06046482 is a clinical study titled "Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma". To learn if magrolimab, along with a combination of commercially-available drugs (cetuximab, pembrolizumab, and docetaxel) can help to control HNSCC in combination with other drugs. The safety of magrolimab will also be studied.
What is the current status of trial NCT06046482?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2023-11-28. Estimated completion is 2024-08-26.
What interventions are being tested in trial NCT06046482?
The interventions under investigation include: Pembrolizumab (DRUG), Docetaxel (DRUG), cetuximab (DRUG), Magrolimab (DRUG).
Who is sponsoring clinical trial NCT06046482?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.